A thirteen‑gene set efficiently predicts the prognosis of glioblastoma
- Authors:
- Published online on: January 2, 2019 https://doi.org/10.3892/mmr.2019.9801
- Pages: 1613-1621
-
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Glioblastoma multiforme (GBM) is the most common and the most invasive subtype of brain cancer; it is characterized by symptoms that include personality changes, headaches, nausea and unconsciousness (1,2). GBM originates from normal brain cells or low-grade astrocytoma, and may be induced by genetic disorders and radiation exposure (3,4). Clinical techniques for the treatment of GBM include surgery combined with radiation therapy or chemotherapy; however, the survival benefit is limited to ~12-15 months, or even shorter if the disease recurs (4).
Gene therapy is a novel strategy for treating cancers (5). Transient receptor potential genes are overexpressed in GBM, which promote the survival of patients (6,7). It has been previously reported that low expression of B cell-specific Moloney murine leukemia virus integration site 1 suppresses proliferation and promotes apoptosis of U251 GBM cells, and enhances the chemosensitivity of these cells to cisplatin (8,9). The expression level of epidermal growth factor-containing fibulin extracellular matrix protein 1 (EFEMP1) was associated with the survival of patients with GBM treated with temozolomide (TMZ) (10); thus, EFEMP1 is considered a target for overcoming TMZ-resistance in GBM. Enhancer of zeste homolog 2 (EZH2) overexpression was associated with tumor grade and predicts short overall survival in patients with GBM (11); thus, EZH2 may be a promising prognostic factor and therapeutic target for patients. Additionally, HOX transcript antisense RNA (HOTAIR) overexpression was associated with poor outcome in patients with GBM, and HOTAIR may be a therapeutic molecular target for this disease (12,13). O-6-Methylguanine-DNA methyltransferase (MGMT) methylation status and mutations in the isocitrate dehydrogenase 1 (IDH1) gene are two known clinicopathological factors linked to overall survival of patients with GBM (14). MGMT methylation is significantly associated with the clinical prognosis of GBM (15); IDH1 is a prognostic marker of GBM, and mutations in this gene diminish the malignant progression of glioma (16). In addition, high expression of interleukin-13R mRNA is strongly associated with poor prognosis of GBM (17). POZ/BTB and AT hook-containing zinc-finger 1 is another prognostic marker of GBM; it is overexpressed in GBM-derived glioma-initiating stem cells, and is associated with the characteristic stem cell capacity to grow as neurospheres in vitro (18). Despite this collective knowledge, the genes involved in the prognosis of GBM have not been comprehensively reported.
In 2008, Murat et al (19) established the GSE7696 gene expression profile, and demonstrated that high expression levels of epidermal growth factor receptor and stem cell-related ‘self-renewal’ signature are involved in the resistance to concomitant chemoradiotherapy of GBM. In 2011, Lambiv et al (20) used the GSE7696 data set to explore the action mechanism of tumor suppressor gene Wnt inhibitory factor 1 (WIF1) in GBM models, and concluded that WIF1 may have a tumor suppressive role in GBM through senescence.
However, this data set has not been fully explored. Using the GSE7696 data, additional key genes associated with the prognosis of GBM were investigated using comprehensive bioinformatics methods, such as survival analysis, enrichment analysis and hierarchical clustering. Results from the present study provided novel insights into the prognosis of GBM and may aid in the development of novel therapeutic approaches.
Materials and methods
Data source
The GSE7696 microarray data set, based on the GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array (Thermo Fisher Scientific, Inc.) platform, along with the corresponding clinical information was downloaded from the Gene Expression Omnibus database (www.ncbi.nlm.nih.gov/geo). The data set included 10 recurrent GBM tissue samples (2 females and 8 males; mean age, 51.31 years), 70 primary GBM tissue samples (19 females and 51 males; mean age, 48.07 years) and 4 normal brain tissue samples (sex and age information not available). All patients participated in a phase II or randomized phase III trial (21,22), with informed consent provided. The GSE7696 data set is available and the study was approved by the local ethics committee (19).
Selection of probes with expression changes in primary GBM tissue samples
The normalized data of GSE7696 were obtained, and the primary GBM tissue samples data were selected to use in the present study. Firstly, the unloaded probes were removed. Subsequently, the probes with varied expressions among 70 different patients with primary GBM were identified by the following steps. Firstly, the variance in probe expression level in each sample was calculated, and probes with variance <20% of the total probe variance were excluded. Secondly, the median probe expression in each sample was calculated and, as in the prior step, probes with a value <20% of the total median probe expression were removed. Finally, the probes with expression changes among these primary GBM tissue samples were selected.
Survival analysis and pathway enrichment analysis
Using the ‘survival’ package (23) in R (www.r-project.org), univariate survival analysis was conducted for the above probes with expression changes, and those with P<0.05 were considered as seed genes. The Kyoto Encyclopedia of Genes and Genomes (KEGG; www.genome.ad.jp/kegg) is a database used to search for gene functions, connecting genomic with functional information (24). Using the DAVID database (david.abcc.ncifcrf.gov) (25), KEGG pathway enrichment analysis was performed for the seed genes to explore their functions. The categories with P<0.05 were considered to indicate a statistically significant difference.
Screening of prognostic feature genes, unsupervised hierarchical clustering and analysis of prognostic characteristics
Using the ‘rbsurv’ package in R (bioconductor.org/packages/release/bioc/html/rbsurv.html) (26), robust likelihood-based survival modeling was constructed to identify prognostic feature genes (27). The samples were classified based on the expression profiles of the prognostic feature genes using unsupervised hierarchical clustering (28). Thereafter, the prognostic differences among the classified samples were analyzed by the Kaplan-Meier survival analysis (29). The expression differences of the feature genes between primary GBM and normal samples were analyzed; and the scatter plot of the gene expression levels were drawn using the corrplot package (https://cran.r-project.org/web/packages/corrplot/vignettes/corrplot-intro.html) in R (version 3.4.4).
Functional and pathway enrichment analysis for the feature genes
The Gene Ontology (GO) database (www.geneontology.org) is used to predict potential functions of genes and their products (30). The prognostic feature genes were examined with GO functional and KEGG pathway enrichment analysis by the ‘clusterProfiler’ package in R (bioconductor.org/packages/release/bioc/html/clusterProfiler.html), with the threshold q-value <0.05 (31).
Multivariate survival analysis
The prognostic feature genes underwent multivariate survival analysis to check their overall influences on prognosis. In addition, the ‘survivalROC’ package in R (cran.r-project.org/web/packages/survivalROC/index.html) was used to draw the receiver operating characteristic (ROC) curve and calculate the area under the ROC curve (AUC) (32). Specifically, the survivalROC package was used to calculate the ‘true positive rate’ and ‘false positive rate’ of each sample, and the differences between the ‘true positive rate’ and ‘false positive rate’ for each sample were subsequently calculated. The sample with the smallest difference value was set as the cut-off in the multifactorial cox regression analysis, and samples with a higher value than this cut-off were deemed as the high-risk group, while those with a lower value were the low-risk group.
Validation of the prognostic feature genes using an independent data set
The GBM dataset in The Cancer Genome Atlas (TCGA; cancergenome.nih.gov) database (downloaded in January 27, 2015; based on the Illumina HiSeq platform, and included RNA-sequencing data in level 3 and clinical follow-up data) was obtained to validate the prognostic feature genes. The 172 samples in the data set comprised 13 recurrent GBM samples, 154 primary GBM samples and 5 adjacent normal tissue samples. Of the 154 primary GBM samples, 2 samples had no survival information. Finally, 152 primary GBM samples were selected for analysis. The data were transformed using log2(x+1), followed by Cox regression analysis using the ‘survival’ package in R to compare the differences of prognosis and recurrence among the samples in different groups. Differences in the identified factors (age and sex distribution) were assessed using R software. The Mann-Whitney test analysis was performed using the respective internal function in R, ‘wilcox.test’. The χ2 value was calculated using the ‘chisq.test’ function in R.
Results
Survival analysis and pathway enrichment analysis for seed genes
The bioinformatics analysis process used in the present study is outlined in Fig. 1. Following calculation of the variance and median for the probes in the 70 primary GBM, a total of 38,370 probes with expression changes were identified. Based on the univariate survival analysis using the ‘survival’ package, a total of 1,785 gene probes significantly correlated with prognosis of GBM were selected as seed genes. KEGG pathway enrichment analysis identified six pathways that were significantly enriched for these seed genes, including ‘ribosome’, ‘regulation of actin cytoskeleton’, ‘endometrial cancer’, ‘pathways in cancer’, ‘amino sugar and nucleotide sugar metabolism’ and ‘non-small cell lung cancer’ (Table I).
Screening of prognostic feature genes, unsupervised hierarchical clustering and analysis of prognostic characteristics
Robust likelihood-based survival modeling identified 13 prognostic feature genes from the 1,785 seed genes, including collagen type XXVIII α1 chain (COL28A1), PDS5 cohesin-associated factor A (PDS5A; also known as sister chromatid cohesion protein 112), zinc-finger DHHC-type containing 2 (ZDHHC2), zinc-finger protein 24 (ZNF24), myosin VA (MYO5A) and myeloid/lymphoid or mixed-lineage leukemia translocated to 4 (MLLT4) (Table II). Unsupervised hierarchical clustering was conducted for these 13 prognostic feature genes. A heat map demonstrated that these genes may be used to classify the 70 primary GBM samples into two clusters: Cluster 1 contained 51 samples and Cluster 2 contained 19 samples (Fig. 2). Subsequently, Kaplan-Meier survival analysis was used to analyze the prognostic differences between the two clusters. Patients in the Cluster 1 and in Cluster 2 had significant differences in their prognosis, which indicated that the 13 prognostic feature genes may effectively differentiate between high-risk and low-risk patients in a clinical setting (Fig. 3A). In addition, the expression levels of the 13 prognostic feature genes were relatively low, which suggested that they had low redundancy (Fig. 3B).
Functional annotation of prognostic feature genes
Using the ‘clusterProfiler’ package, functional annotation of the prognostic feature genes were conducted. The results identified three genes, including, natriuretic peptide receptor 3 (NPR3), ANKH inorganic pyrophosphate transport regulator and OTU deubiquitinase, ubiquitin aldehyde binding 1 (OTUB1) were significantly enriched in functions, including ‘natriuretic peptide receptor activity’, ‘inorganic phosphate transmembrane transporter activity’ and ‘NEDD8-specific protease activity’, respectively. In addition, myeloid/lymphoid or mixed-lineage leukemia translocated to 4 (MLLT4; also known as afadin, adherens junction formation factor) was indicated to be involved in six KEGG pathways, including ‘adherens junction’, ‘leukocyte transendothelial migration’, ‘tight junction’, ‘cAMP signaling pathway’, ‘Rap1 signaling pathway’ and ‘Ras signaling pathway’. COL28A1, PDS5A, ZDHHC2 and MYO5A were enriched in ‘collagen biosynthesis and modifying enzymes’, ‘separation of sister chromatids’, ‘surfactant metabolism’ and ‘regulation of actin dynamics for phagocytic cup formation’ pathways, respectively.
Multivariate survival analysis
To check the overall influence of the prognostic feature genes on prognosis, multivariate survival analysis was carried out. These genes were classified as having a positive effect on prognosis (area under the ROC curve=0.826) for the 70 primary GBM samples (Fig. 4A). Furthermore, Kaplan-Meier survival analysis demonstrated that the samples in the high-risk and low-risk groups differed significantly in their prognosis (P=5.67×10−12; Fig. 4B), which indicated that the 13 prognostic feature genes may effectively distinguish samples with a different prognostic risk.
Validation of the prognostic feature genes using another independent data set
The GBM data set was downloaded from the TCGA database and used to validate the prognostic feature genes. Survival analysis demonstrated that the 13 prognostic feature genes had good classification effects on samples in the validation data set (area under the ROC curve =0.886) (Fig. 5A). The high-risk and low-risk groups differed significantly in their prognosis (P=5.00×10−5; Fig. 5B). Furthermore, age distribution analysis of the classified primary GBM samples demonstrated that samples in the high-risk and low-risk groups differed significantly in age, with the high-risk group being older than the low-risk group (61.54 vs. 56.96; P=0.04396; Table III). There was no significant difference concerning sex distribution of the classified samples.
Discussion
In the present study, a total of 1,785 gene probes with significant prognostic differences were selected as seed genes. From these, 13 prognostic feature genes, including COL28A1, PDS5A, ZDHHC2, ZNF24, MYO5A, MLLT4, NPR3, ANKH and OTUB1, were further screened. The prognostic feature genes performed well for the classification of samples into different prognostic risk categories. Additionally, the GBM data set downloaded from the TCGA database further confirmed the association of the 13 prognostic feature genes with the prognosis of GBM.
Collagen XVI may promote the invasion of glioma cells by damaging cell-cell interactions or mediating the β1-integrin activation pattern, which provides new approaches for treating cancer in neuro-oncology (33). Fibrillar collagens and the collagen internalization receptor, endocytic receptor 180 (Endo180), are overexpressed in GBM (34). Additionally, Endo180 affects the invasion and progression of tumors (34). Collagen type I α1 (CO1A1) was reported to serve a suppressive biological role in the progression of glioma, suggesting that it may be applied to treating the disease (35). The COL28A1 protein is a filament-forming collagen and is detected in the adult sciatic nerve (36). In our study, COL28A1 was enriched in ‘collagen biosynthesis and modifying enzymes’ pathway. Therefore, COL28A1 may serve a role in the progression of GBM.
PDS5A is tissue-specific and has two-fold effects in tumorigenesis, acting as a tumor suppressor or an oncogenic factor to promote tumor proliferation (37). PDS5A was previously reported to be overexpressed in high-grade gliomas and is positively associated with the World Health Organization grade of gliomas (37). Based on our enrichment result, PDS5A was involved in ‘separation of sister chromatids’ pathway, indicating it might influence the tumor's DNA synthesis phase in GBM development.
ZDHHC2 on chromosome 8p21.3–22 belongs to the DHHC-domain protein family of protein acyltransferases (38). As the largest transcription factor family in humans, zinc-finger proteins serve roles in multiple biological processes, including autophagy, metabolism, development and differentiation, and in cancer progression (39). In addition, ZDHHC2 is associated with prognosis in a number of types of cancer. In gastric cancer, decreased ZDHHC2 expression is associated with lymph node metastasis and indicates a poor prognosis (40). In the present study, ZDHHC2 was highly associated with the ‘surfactant metabolism’ pathway and identified as a prognostic gene in GBM, suggesting that it might have an important role in GBM prognosis.
ZNF24 plays a critical role in brain development and various cancer types. Furthermore, ZNF24 may contribute to cell cycle promotion and maintenance of the progenitor stage of neural cells (41). Platelet-derived growth factor receptor (PDGFR) signaling is a crucial mechanism for the initiation and development of GBM (42). In GBM cell lines, ZNF24 negatively regulates two transcription factors, vascular endothelial growth factor (VEGF) and PDGFR-β (43).
In the present study, the above three genes were among the 13 crucial prognostic genes of GBM. The collective findings implicate PDS5A, ZDHHC2 and ZNF24 are involved in the pathogenesis of GBM. Although no studies have reported the potential roles of ZDHHC2 in GBM, this gene may also be associated with the prognosis of GBM, based on our results.
Myosin II is required for the invasion of glioma cells and is a promising target for the anti-invasive treatment of malignant brain tumors (44,45). In 1321N1 GBM cells, MYO1C is crucial for lamellipodia formation to produce a protein complex promoting cell migration (46). MYO6 was implicated in human glioma and its inhibition may be a promising therapeutic method for the disease (47). The activation of myosin-associated contractility sensitizes GBM tumor-initiating cells, which subsequently weakens the invasive ability of the cells (48). In the present study, MYO5A was enriched in ‘regulation of actin dynamics for phagocytic cup formation’. Thus, MYO5A may serve a role in the progression of GBM.
MLLT4 is one of the aliases of the gene, afadin, adherens junction formation factor, which belongs to an adhesion system and encodes a protein participating in cell junctions during embryogenesis. Neurofibromin 1 (NF1) mutations have been identified in several cancer types, including GBM (49). Furthermore, in a mouse model of NF1-associated optic pathway gliomas (OPG), cyclic adenosine 3′,5′-monophosphate (cAMP) inhibits the growth of OPG (50). Notably, MLLT4 is one of the NF1-regulated effectors downstream of RAS (51). Results from the present studies support the possible importance of MLLT4 in GBM pathogenesis through the participation in the adherens junction, cAMP signaling and Ras signaling pathways. In addition, a number of pathways, such as leukocyte transendothelial migration, are enriched in GBM-derived extracellular vesicles (EVs), which suggested that GBM cells may exhibit mechanisms to selectively combine these proteins in EVs (52). In the present study, leukocyte transendothelial migration was one of the six enriched pathways identified for MLLT3; therefore, this pathway may also be an important regulation target in GBM development. With regard to the tight junction pathway, junctional adhesion molecule (JAM) is one family of the immunoglobulin-like superfamily expressed in tight junctions, and abnormal JAM-A expression was reported to contribute to the progression of GBM (53). This may be evidence of the gene expression alterations in the tight junction pathway in the development of GBM.
NPR3 encodes a natriuretic peptide receptor, which regulates metabolic processes. A long noncoding RNA (lncRNA), BCYRN1, has an oncogenic role in colorectal cancer cells by upregulating NPR3 expression (54). In clear cell renal cell carcinoma (ccRCC), the lncRNA MRCCAT1 has been observed to promote ccRCC metastasis by inhibiting NPR3 (55). ANKH is identified as a novel putative oncogene in small cell lung cancer cell lines (56). In cervical cancer, ANKH is also suggested as an oncogene and the upregulation is validated by reverse transcription-quantitative polymerase chain reaction (57). To the best of our knowledge, there have been no studies reporting an association between these two genes, NPR3 and ANKH, and glioma. However, in the present study, these were important prognostic genes of GBM and were enriched in crucial pathways, suggesting that they may be novel markers in GBM and correlate with prognosis.
The OTUB1 protein is a deubiquitinating enzyme. In glioma tissues, expression of OTUB1 is increased and the expression level is associated with the glioma grade; on the other hand, knockdown of OTUB1 suppresses the tumor cell migration (58). This finding suggests that OTUB1 serves an important role in the etiology of glioma (58).
However, all these predictive results need to be further validated by in vitro and in vivo experiments. Notably, patients in the high-risk group were slightly older compared with patients in the low-risk group; although the difference was minor, it was significant. A previous study identified age as a risk factor for the process of dexamethasone-induced leukocytosis, which is associated with poor survival in the newly diagnosed GBM (59). Therefore, the present study suggested that age may be a risk factor of GBM, but this needs to be validated using larger data sets.
In conclusion, the 13-gene set was tested and verified, and very efficiently predicted the prognosis of GBM in independent data sets. In addition, COL28A1, PDS5A, ZDHHC2, ZNF24, MYO5A and MLLT4 were implicated as key genes involved in the prognosis of GBM. The adherens junction, cAMP and Ras signaling pathways may be important in the progression of GBM, and age may be a risk factor for prognosis.
Acknowledgements
Not applicable.
Funding
No funding was received.
Availability of data and materials
The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.
Authors' contributions
HY performed data analyses and wrote the manuscript. LJ contributed significantly to the data analysis and manuscript revision. XS conceived and designed the study. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
Bleeker FE, Molenaar RJ and Leenstra S: Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 108:11–27. 2012. View Article : Google Scholar : PubMed/NCBI | |
Young RM, Jamshidi A, Davis G and Sherman JH: Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. 3:1212015.PubMed/NCBI | |
McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gallego O: Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 22:e273–e281. 2015. View Article : Google Scholar : PubMed/NCBI | |
Fulci G and Chiocca EA: The status of gene therapy for brain tumors. Expert Opin Biol Ther. 7:197–208. 2007. View Article : Google Scholar : PubMed/NCBI | |
Alptekin M, Eroglu S, Tutar E, Sencan S, Geyik MA, Ulasli M, Demiryurek AT and Camci C: Gene expressions of TRP channels in glioblastoma multiforme and relation with survival. Tumor Biology. 36:9209–9213. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Luan Y, Yu R, Zhang Z, Zhang J and Wang W: Transient receptor potential (TRP) channels, promising potential diagnostic and therapeutic tools for cancer. Biosci Trends. 8:1–10. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hong Y, Shang C, Xue YX and Liu YH: Silencing of Bmi-1 gene enhances chemotherapy sensitivity in human glioblastoma cells. Med Sci Monit. 21:1002–1007. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ye L, Wang C, Yu G, Jiang Y, Sun D, Zhang Z, Yu X, Li X, Wei W, Liu P, et al: Bmi-1 induces radioresistance by suppressing senescence in human U87 glioma cells. Oncol Lett. 8:2601–2606. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hiddingh L, Tannous BA, Teng J, Tops B, Jeuken J, Hulleman E, Boots-Sprenger SH, Vandertop WP, Noske DP, Kaspers GJ, et al: EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget. 5:363–374. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Chen L, Han L, Shi Z, Zhang J, Pu P and Kang C: EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Cancer Lett. 356:929–936. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhou X, Ren Y, Zhang J, Zhang C, Zhang K, Han L, Kong L, Wei J, Chen L, Yang J, et al: HOTAIR is a therapeutic target in glioblastoma. Oncotarget. 6:8353–8365. 2015.PubMed/NCBI | |
Zhang K, Sun X, Zhou X, Han L, Chen L, Shi Z, Zhang A, Ye M, Wang Q, Liu C, et al: Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner. Oncotarget. 6:537–546. 2015.PubMed/NCBI | |
Insin P and Prueksaritanond N: Evaluation of four risk of malignancy indices (RMI) in the preoperative diagnosis of ovarian malignancy at Rajavithi hospital. Thai J Obstet Gynaecol. 21:2013. | |
Sim J, Nam DH, Kim Y, Lee IH, Choi JW, Sa JK and Suh YL: Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. Med Oncol. 35:602018. View Article : Google Scholar : PubMed/NCBI | |
Yao Q, Cai G, Yu Q, Shen J, Gu Z, Chen J, Shi W and Shi J: IDH1 mutation diminishes aggressive phenotype in glioma stem cells. Int J Oncol. 52:270–278. 2017.PubMed/NCBI | |
Han J and Puri RK: Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol. 136:463–474. 2018. View Article : Google Scholar : PubMed/NCBI | |
Guadagno E, Vitiello M, Francesca P, Calì G, Caponnetto F, Cesselli D, Camorani S, Borrelli G, Califano M, Cappabianca P, et al: PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. Oncotarget. 8:59282–59300. 2017. View Article : Google Scholar : PubMed/NCBI | |
Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, et al: Stem cell-related ‘self-renewal’ signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 26:3015–3024. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, et al: The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol. 13:736–747. 2011. View Article : Google Scholar : PubMed/NCBI | |
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI | |
Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 20:1375–1382. 2002. View Article : Google Scholar : PubMed/NCBI | |
Therneau TM: Survival analysis (R package survival version 2.39–5). 2015. | |
Kanehisa M, Sato Y, Kawashima M, Furumichi M and Tanabe M: KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44:D457–D62. 2015. View Article : Google Scholar : PubMed/NCBI | |
Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Boil. 8:R1832007. View Article : Google Scholar | |
Cho HJ, Kim S, Kang J and Lee JW: How to use the rbsurv Package. 2010. | |
Renaud G, Stenzel U, Maricic T, Wiebe V and Kelso J: deML: Robust demultiplexing of Illumina sequences using a likelihood-based approach. Bioinformatics. 31:770–772. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang SJ: Unsupervised hierarchical clustering based on sequential partitioning and merging. International Symposium on Vlsi Design, Automation and Test. 2016. | |
Porcher R: CORR Insights(®): Kaplan-meier survival analysis overestimates the risk of revision arthroplasty: A meta-analysis. Clin Orthop Relat Res. 473:3431–3442. 2015. View Article : Google Scholar : PubMed/NCBI | |
Smith B, Williams J and Schulze-Kremer S: The ontology of the gene ontology. AMIA Annu Symp Proc. 609–613. 2003.PubMed/NCBI | |
Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI | |
Heagerty PJ, Thomas L and Pepe MS: Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bauer R, Ratzinger S, Wales L, Bosserhoff A, Senner V, Grifka J and Grässel S: Inhibition of collagen XVI expression reduces glioma cell invasiveness. Cell Physiol Biochem. 27:217–226. 2011. View Article : Google Scholar : PubMed/NCBI | |
Huijbers IJ, Iravani M, Popov S, Robertson D, Alsarraj S, Jones C and Isacke CM: A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS One. 5:e98082010. View Article : Google Scholar : PubMed/NCBI | |
Honma K, Miyata T and Ochiya T: Type I collagen gene suppresses tumor growth and invasion of malignant human glioma cells. Cancer Cell Int. 7:122007. View Article : Google Scholar : PubMed/NCBI | |
Veit G, Kobbe B, Keene DR, Paulsson M, Koch M and Wagener R: Collagen XXVIII, a novel von Willebrand factor A domain-containing protein with many imperfections in the collagenous domain. J Biol Chem. 281:3494–3504. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hagemann C, Weigelin B, Schommer S, Schulze M, Al-Jomah N, Anacker J, Gerngras S, Kühnel S, Kessler AF, Polat B, et al: The cohesin-interacting protein, precocious dissociation of sisters 5A/sister chromatid cohesion protein 112, is up-regulated in human astrocytic tumors. Int J Mol Med. 27:39–51. 2011.PubMed/NCBI | |
Oyama T, Miyoshi Y, Koyama K, Nakagawa H, Yamori T, Ito T, Matsuda H, Arakawa H and Nakamura Y: Isolation of a novel gene on 8p21.3-22 whose expression is reduced significantly in human colorectal cancers with liver metastasis. Genes Chromosomes Cancer. 29:9–15. 2000. View Article : Google Scholar : PubMed/NCBI | |
Jen J and Wang YC: Zinc finger proteins in cancer progression. J Biomed Sci. 23:532016. View Article : Google Scholar : PubMed/NCBI | |
Yan SM, Tang JJ, Huang CY, Xi SY, Huang MY, Liang JZ, Jiang YX, Li YH, Zhou ZW, Ernberg I, et al: Reduced expression of ZDHHC2 is associated with lymph node metastasis and poor prognosis in gastric adenocarcinoma. PLoS One. 8:e563662013. View Article : Google Scholar : PubMed/NCBI | |
Khalfallah O, Ravassard P, Che SL, Fligny C, Serre A, Bayard E, Faucon-Biguet N, Mallet J, Meloni R and Nardelli J: Zinc finger protein 191 (ZNF191/Zfp191) is necessary to maintain neural cells as cycling progenitor. Stem Cells. 27:1643–1653. 2009. View Article : Google Scholar : PubMed/NCBI | |
Carrasco-Garcia E, Martinez-Lacaci I, Mayor-López L, Tristante E, Carballo-Santana M, García-Morales P, Ventero Martin MP, Fuentes-Baile M, Rodriguez-Lescure Á and Saceda M: PDGFR and IGF-1R inhibitors induce a G2/M arrest and subsequent cell death in human glioblastoma cell lines. Cells. 7:E1312018. View Article : Google Scholar : PubMed/NCBI | |
Li JZ, Chen X, Liu Y, Ding L, Qiu L, Hu ZL and Zhang J: The transcriptional repression of platelet-derived growth factor receptor-beta by the zinc finger transcription factor ZNF24. Biochem Biophys Res Commun. 397:318–322. 2010. View Article : Google Scholar : PubMed/NCBI | |
Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS and Canoll P: The role of myosin II in glioma invasion of the brain. Mol Biol Cell. 19:3357–3368. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ivkovic S, Beadle C, Noticewala S, Massey SC, Swanson KR, Toro LN, Bresnick AR, Canoll P and Rosenfeld SS: Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens. Mol Biol Cell. 23:533–542. 2011. View Article : Google Scholar | |
Edimo WE, Ramos AR, Ghosh S, Vanderwinden JM and Erneux C: The SHIP2 interactor Myo1c is required for cell migration in 1321 N1 glioblastoma cells. Biochem Biophys Res Commun. 476:508–514. 2016. View Article : Google Scholar : PubMed/NCBI | |
Xu R, Fang XH and Zhong P: Myosin VI contributes to malignant proliferation of human glioma cells. Korean J Physiol Pharmacol. 20:139–145. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wong SY, Ulrich TA, Deleyrolle LP, MacKay JL, Lin JM, Martuscello RT, Jundi MA, Reynolds BA and Kumar S: Constitutive activation of myosin-dependent contractility sensitizes glioma tumor-initiating cells to mechanical inputs and reduces tissue invasion. Cancer Res. 75:1113–1122. 2015. View Article : Google Scholar : PubMed/NCBI | |
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al: The somatic genomic landscape of glioblastoma. Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI | |
Warrington NM, Sun T, Luo J, Mckinstry RC, Parkin PC, Ganzhorn S, Spoljaric D, Albers AC, Merkelson A, Stewart DR, et al: The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. Cancer Res. 75:16–21. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kiuru M and Busam KJ: The NF1 gene in tumor syndromes and melanoma. Lab Invest. 97:146–157. 2017. View Article : Google Scholar : PubMed/NCBI | |
de Vrij J, Maas SL, Kwappenberg KM, Schnoor R, Kleijn A, Dekker L, Luider TM, de Witte LD, Litjens M, van Strien ME, et al: Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells. Int J Cancer. 137:1630–1642. 2015. View Article : Google Scholar : PubMed/NCBI | |
Leech AO, Cruz RG, Hill AD and Hopkins AM: Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. Ann Transl Med. 3:1842015.PubMed/NCBI | |
Gu L, Lu LS, Zhou DL and Liu ZC: Long noncoding RNA BCYRN1 promotes the proliferation of colorectal cancer cells via Up-regulating NPR3 expression. Cell Physiol Biochem. 48:2337–2349. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li JK, Chen C, Liu JY, Shi JZ, Liu SP, Liu B, Wu DS, Fang ZY, Bao Y, Jiang MM, et al: Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling. Mol Cancer. 16:1112017. View Article : Google Scholar : PubMed/NCBI | |
Coe BP, Henderson LJ, Garnis C, Tsao MS, Gazdar AF, Minna J, Lam S, Macaulay C and Lam WL: High-resolution chromosome arm 5p array CGH analysis of small cell lung carcinoma cell lines. Genes Chromosomes Cancer. 42:308–313. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kloth JN, Oosting J, van Wezel T, Szuhai K, Knijnenburg J, Gorter A, Kenter GG, Fleuren GJ and Jordanova ES: Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics. 8:532007. View Article : Google Scholar : PubMed/NCBI | |
Xu L, Li J, Bao Z, Xu P, Chang H, Wu J, Bei Y, Xia L, Wu P, Yan K, et al: Silencing of OTUB1 inhibits migration of human glioma cells in vitro. Neuropathology. 37:217–226. 2017. View Article : Google Scholar : PubMed/NCBI | |
Dubinski D, Won SY, Gessler F, Quick-Weller J, Behmanesh B, Bernatz S, Forster MT, Franz K, Plate KH, Seifert V, et al: Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma. J Neurooncol. 137:503–510. 2018. View Article : Google Scholar : PubMed/NCBI |